PubMed · 11263652
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
J L Chang. 2001. Diagnostic bone-density testing.. https://doi.org/10.2106/00004623-200103000-00023
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
OBJECTIVES: The aim of this study was to observe hysterectomized postmenopausal women (without progestogen, which could interfere in the results), using oral-conjugated oestrogen 0.625 mg daily (n=13) or 17beta-estradiol transdermal patches delivering 50 microg daily (n=10) during 12 months, and to evaluate the treatment effects on body composition, visceral fat distribution, energy expenditure and substrate oxidation. METHODS: We studied 23 postmenopausal women using oral-conjugated oestrogen (Premarin) 0.625 mg daily (n=13) or transdermal oestrogen patches (Systen TTS) 50 microg daily (n=10). Body composition was measured by DEXA, visceral adipose tissue areas were measured by abdominal computed tomography, and energy expenditure, fat oxidation and carbohydrate oxidation were measured by indirect calorimetry (Deltatrac Metabolic Monitor). RESULTS: There were: (1) a decrease in IGF-I and an increase in GH levels in the oral group and no change in the transdermal group; (2) a increase in lean body mass in the transdermal group and a decrease in the oral group; (3) a increase in total body fat mass in the oral group and no change in the transdermal group; (4) an increases in total bone mass and in total bone mineral density in the transdermal group and no change in the oral group; (5) an increase in lipid oxidation in the transdermal group and a decrease in the oral group, and (6) no significantly change about weight, visceral adipose tissue areas and energy expenditure in both groups. CONCLUSIONS: The administration route of oestrogen replacement therapy in postmenopausal women confers distinct and divergent effects on body composition and substrate oxidation during 12-months treatment.
UNLABELLED: To evaluate the effect of gonadotrophin-releasing hormone (GnRH) agonist treatment on bone quality at final height, we studied girls with central precocious puberty (CPP) and with idiopathic short stature (ISS). A total of 25 Caucasian girls were included: group A (n=14) with idiopathic CPP (mean age at start 7.4 years) and group B (n=11) with ISS (mean age at start 11.7 years). Treatment duration was 3.8 and 1.7 years respectively. The quantitative ultrasound parameters (QUS) broadband ultrasound attenuation (BUA) and speed of sound (SOS) were measured at the calcaneus (UBIS 3000 device). Lumbar spine bone mineral density (BMD; L2-L4) was measured by dual energy X-ray absorptiometry (DXA) (Hologic QDR1000). Measurements were performed at final height and expressed as Z-scores corrected for bone age. Mean Z-scores of QUS parameters, areal BMD and volumetric BMD (BMDvol) were above -1 in both groups (group A: BUA Z-score -0.21, SOS Z-score -0.29, BMD Z-score 0.02, BMDvol Z-score 0.05, group B: BUA Z-score -0.93, SOS Z-score -0.40, BMD Z-score -0.86, BMDvol Z-score -0.68), although mean Z-scores of BUA and areal BMD in group B were significantly different from zero (P=0.03 and P=0.02 respectively). Mean Z-score BMDvol was not significantly different from zero (P=0.05), we found no significant difference between the groups for BMDvol (P=0.13). CONCLUSION: Although quantitative ultrasound parameters parameters and bone mineral density were normal in girls with central precocious puberty at final height after gonadotrophin-releasing hormone agonist treatment, mean Z-score for broadband ultrasound attenuation and areal bone mineral density were significantly different from zero and mean Z-score for volumetric bone mineral density was (just) not significantly different from zero in idiopathic short stature girls with normal puberty treated with gonadotrophin-releasing hormone agonists. Therefore we cannot say that this treatment is safe in these girls with regard to bone health.
This study examined whether participation in high-impact sports during adolescence and adulthood contributes to bone health in males aged 40 years. Data were analyzed on 154 Belgian men aged 13 years at study onset in 1969 and aged 40 years at the end of the 27-year follow-up. In a second analysis, subjects were divided into three groups according to their sports participation history: participation during adolescence and adulthood in high-impact sports (HH; n=18), participation during adolescence in high-impact sports and during adulthood in nonimpact sports or no sports (HN; n=15), and participation during adolescence and adulthood in nonimpact sports or no sports (NN; n=14). Body mass and impact loading during adulthood were significant predictors of total body bone mineral density (BMD) and lumbar spine BMD. Analysis of variance revealed significant differences for lumbar spine BMD between the HH (1.12 g/cm2) group and the HN (1.01 g/cm2) and NN (0.99 g/cm2) groups (F=5.07, p=0.01). Total body BMD was also higher in the HH group at age 40 years, but not significantly (F=3.17, p=0.0515). Covariance analyses for total body BMD and lumbar spine BMD, with body mass and time spent participating in sports as covariates, confirmed these results. Continued participation in impact sports is beneficial for the skeletal health of males aged 40 years.